A multiscale approach to targeted docetaxel formulations: combination therapy, nanotechnology, electrospinning and 3D printing—a review

Oyediran, Karamot O.; Ilomuanya, Margaret O.; Azubuike, Chukwuemeka P.; Nurudeen, Layeni

doi:10.1186/s42269-022-00854-5

Bulletin of the National Research Centre

Table 1 Drugs coadministered with docetaxel for optimized chemotherapeutic action

From: A multiscale approach to targeted docetaxel formulations: combination therapy, nanotechnology, electrospinning and 3D printing—a review

Tumor type	Coformulated drug(S)	Mode of administration	Clinical trial	Remark	References
Metastatic breast cancer	Trastuzumab	IV infusion	Phase II human study	Prolonged progression time with minimal toxicities	Esteva et al. (2002)
HER2 positive metastatic breast cancer	Trastuzumab	Intravenous infusion	Phase II human trials	Greater efficacy with minimal toxicity	Marty et al. (2005)
Prostate cancer	ABT 627	Intravenous infusion	Preclinical studies (in vivo and in vitro)	ABT 627 enhances sensitivity of tumor cells to docetaxel, hence enhancing docetaxel induced growth inhibition	Banerjee et al. (2007)
HER2 negative metastatic breast cancer	Bevacizumab	IV infusion	Phase III trials	Enhanced progression free survival with limited increase in toxicity	Miles et al. (2010)
HER2 Metastatic breast cancer	Pertuzumab and trastuzumab	IV infusion	Phase II human study	Prolonged survival with no disease progression when compared with trastuzumab/docetaxel only	Baselga et al. (2012)
Refractory tumors	Ritonavir	Oral	Phase II clinical trial	Comparable efficacy of combined drug in capsule and DTX/RTV separately	Moes et al. (2013)
Metastatic breast cancer	Capecitabine	Intravenous	Phase 1II human trials	Prolonged progression time with combination when compared with docetaxel alone	Glück et al. (2013)
Metastatic triple negative breast cancer	Cisplatin	Intravenous infusion	Phase II clinical trials	Cisplatin/DTX more effective than capecitabine/DTX	Fan et al. (2013)
Advanced recurrent non-small cell lung cancer	Ramucirumab	IV Infusion	Retrospective study in Human subject	Combination more effective, delays disease progression	Harada et al. (2019)
Advanced or metastatic solid tumors	Ritonavir	Oral	Phase 1 clinical trial	75% of subject did not experience toxic side effects. Twofold increase in Cmax when combined with RTV	Vermunt et al. (2021a, b)

Back to article page